SGLT2 Inhibitors Treatment Market Size & Share, By Application (Glucose Dissipation, Blood Transfusion); End-user (Hospitals, Clinics, Diagnostic Centres) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

Request Free Sample Copy

Report ID: 3972
Published Date: Aug 25, 2023
Report Format: PDF, PPT

Buy Now

Companies Dominating the SGLT2 Inhibitors Treatment Landscape

Novartis International AG

Company overview
Business strategy
Key product offerings
Financial performances
Key performance indicators
Risk analysis
Recent development
Regional presence
SWOT analysis

Boehringer Ingelheim GmbH
Janssen pharmaceuticals
GRUPO TECNIMEDE
Unichem Laboratories Ltd.
Edificio Bluepharma

Browse Key Market Insights with Data Illustration:

SGLT2 Inhibitors Treatment Market Size & Share, Growth Forecasts 2035

In the News

Astellas Pharma Inc., announced that selective SGLT2 inhibitor Suglat Tablets 25mg and 50mg Ipragliflozin L-Proline, “Suglat Tablets”) became available for the indication of type 2 diabetes in the Japanese market today.
AstraZeneca’s Forxiga (dapagliflozin) was approved in China to reduce the risk of cardiovascular (CV) death and hospitalization for heart failure in adults with heart failure (NYHA class II-IV) with reduced ejection fraction (HFrEF).

Frequently Asked Questions (FAQ)

Growing Concern for the Prevalence of diabetes mellitus is estimated to boost the SGLT2 inhibitor treatment market.

The market size of SGLT2 inhibitors treatment market is anticipated to attain a CAGR of 9% over the forecast period, i.e., 2023 â€“ 2035.

The major players in the market are Novartis International AG, Boehringer Ingelheim GmbH, Janssen pharmaceutical, GRUPO TECNIMEDE, Unichem laboratories ltd, Edificio blue pharma, AstraZeneca Pharmaceuticals LP, Eli Lily and company, the mercy group, Pfizer Inc.

The hospital segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

The market in the North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

SGLT2 Inhibitors Treatment Market Size & Share, By Application (Glucose Dissipation, Blood Transfusion); End-user (Hospitals, Clinics, Diagnostic Centres) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

Companies Dominating the SGLT2 Inhibitors Treatment Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

What are the major factors driving the growth of the SGLT2 Market?

What would be the CAGR of the SGLT2 Inhibitors Treatment market over the forecast period?

Who are the major players dominating the SGLT2 inhibitors treatment market?

Which segment captures the largest market size in the end-user segment in the SGLT2 market?

Which region will provide more business opportunities for the growth of the SGLT2 inhibitor treatment market in the future?